CTIS2023-507073-18-00招募中1 期
A novel COMBinATorial therapy with albumin and enoxaparin in patients with decompensated cirrhosis at high-risk of poor outcome (COMBAT trial). - COMBAT
European Foundation For The Study Of Chronic Liver Failure0 个研究点目标入组 90 人开始时间: 2023年8月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age between 18 and 80 years, Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive-related gastrointestinal bleeding, bacterial infection, or any combination of these)., CLIF-C AD score >= 50 at admission or at any time during hospital stay., Recovery from AD and expected to be discharged within the next 72 hours.
排除标准
- •Diagnosis of acute-on-chronic liver failure (ACLF) grade 2 or higher according to the EASL-CLIF criteria at admission or at any time during the index hospitalization, Ongoing anti-platelets therapy., Active malignancy (except for hepatocellular carcinoma within the Milan criteria or non-melanocytic skin cancer), Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months, Ongoing alcohol use disorder with an expected low adherence to protocol as judged by physician, Previous liver transplantation, Patients with TIPS or other surgical porto-caval shunts, Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate <30 ml/min according to the MDRD equations, Chronic heart failure NYHA class III or IV, Pulmonary disease GOLD III or IV, Patients with extrahepatic diseases with life expectancy <6 months, Admission for planned diagnostic or therapeutic procedures, Severe psychiatric disorders, Hypersensitivity to albumin preparations or to any of the excipients, Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWH) or to any of the excipients, History of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies, Pregnancy and breast-feeding, Expected low adherence to study protocol as judged by physician, Patients who can’t provide written informed consent or refusal to participate, Participation in other concurrent clinical trials and within the prior 3 months from informed consent signature., Recent acute bleeding (unless the cause has been effectively treated and there is no evidence of ongoing bleeding for at least 5 days), Chronic bleeding requiring periodic blood transfusions, Presence of an ongoing acute complication of the disease (i.e. hepatic encephalopathy [grade III or IV]), Conditions with a high risk of haemorrhage, including haemorrhagic diathesis not related to liver disease, Patients with INR > 3.0, Severe thrombocytopenia (<30x109/L), Ongoing chronic anticoagulation therapy or indication for starting anticoagulation due to hepatic and non-hepatic conditions
研究者
相似试验
招募中
2 期
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).Liver CirrhosisNCT05895136European Foundation for Study of Chronic Liver Failure90
招募中
不适用
Study of combination chemotherapy of Albumin-bound paclitaxel / Cyclophosphamide in recurrent or metastatic breast cancerBreast cancerJPRN-UMIN000009616Yokohama City University Medical Center30
招募中
3 期
Treatment of pleural effusion by albumin and lasixPleural effusion.Pleural effusion, not elsewhere classifiedIRCT20180520039739N4Esfahan University of Medical Sciences50
招募中
不适用
Comparison between Standard medical therapy plus intravenous albumin vs standard medical therapy alone in patients with variceal upper gastrointestinal bleed.CTRI/2022/10/046898All India Institute of Medical Sciences
已完成
不适用
Parenteral albumin therapy in patients with extensive BurEffect of albumin on burn wound healing.Sequelae of protein-energy malnutritionIRCT138802141605N3Vice-chancellor for Research140